Clinical Trial Update: Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of PRX-03140 as monotherapy in Alzheimer's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PRX-03140

Snippet

Sponsor: Epix Pharmaceuticals, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED